Clinical results for Supera highlighted at LINC

WEBSTER, Texas and LEIPZIG -- At the Leipzig Interventional Course (LINC) in Leipzig, Germany, physicians from the United States and Europe presented data on their clinical experience with the Supera stent from IDEV Technologies. LINC is a meeting forum of global interdisciplinary physicians focusing on endovascular peripheral interventional treatments.

Results on over 1,000 treated patients were compiled and presented, including findings from these four new studies:

-- Supera Interwoven Nitinol Stent Outcomes in Above-Knee interventions (SAKE) study from the Deborah Heart and Lung Center, Brown Hills, NJ;

-- Antwerp Supera in Popliteal & Superficial Femoral Artery (AURORAA) study from Vascular Clinik ZNA, Antwerp, Belgium;

-- Real World experience with the Supera stentin the SFA and Popliteal arteries from Tucson Medical Center, Tucson, AZ; and

-- IDEV Supera Stenting to Preserve Dialysis Access from Lawrenceville, GA.

"All data presented at LINC represents a broad range of patients affected by peripheral vascular disease in the popliteal and SFA arteries, and dialysis fistulas," said Dennis Donohoe, MD, chief medical officer for IDEV Technologies, Inc., manufacturer of the Supera stent . "These are real-world patients with advanced complex disease, the type that confronts physicians on a daily basis."

1-year primary patency results

The primary clinical outcome of two of these 4 new studies was primary patency demonstrating independent, consistent and impressive 1-year primary patency results of 86% (AURORAA) and 88% (Real World, Tucson) with the third study SAKE, producing a 92% Freedom from Target Lesion Revascularization (TLR). These individual study results are consistent with the results reported last October at VIVA on IDEV's SUPERB IDE trial of 264 patients (86% patency at one year by duplex ultrasound, theAir Force 1 Low Upstep BR